Sale of QVQ Holdings BV shares -- 121
-------------------------------------------- ------ ------
Net cash used in investing activities (328) (509)
-------------------------------------------- ------ ------
Financing activities:
Proceeds on share issuance, net of
transaction costs 1,507 --
Repayment of leases (801) (715)
Proceeds on debenture issuance, net
of transaction costs 4,059 --
---------------------------------------- ------ ------
Net cash provided by (used in) financing
activities 4,765 (715)
-------------------------------------------- ------ ------
Increase (decrease) in cash during the
period 370 (1,794)
Foreign exchange (294) (468)
Cash -- beginning of the period 3,545 8,366
-------------------------------------------- ------ ------
Cash -- end of the period 3,621 6,104
-------------------------------------------- ------ ------
Cash is comprised of:
Cash 3,534 6,017
Restricted cash 87 87
-------------------------------------------- ------ ------
3,621 6,104
---------------------------------------- ------ ------
Cash paid for interest -- --
Cash paid for income tax -- --
-------------------------------------------- ------ ------
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210683224/en/
CONTACT:
Investor Relations Contact
investors@ipatherapeutics.com
(END) Dow Jones Newswires
December 10, 2024 08:30 ET (13:30 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。